Abstract L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective drug in the symptomatic treatment of Parkinson's disease, but chronic use is associated with L-DOPA-induced dyskinesia in more than half the patients after 10 years of treatment. L-DOPA treatment may affect tryptophan metabolism via the kynurenine pathway. Altered levels of kynurenine metabolites can affect glutamatergic transmission and may play a role in the development of L-DOPA-induced dyskinesia. In this study, we assessed kynurenine metabolites in plasma and cerebrospinal fluid of Parkinson's disease patients and controls. Parkinson patients (n = 26) were clinically assessed for severity of motor symptoms (UPDRS) and L-DOPA-induced dyskinesia (UDysRS). Plasma and cerebrospinal fluid samples were collected after overnight fasting and 1-2 h after intake of L-DOPA or other anti-Parkinson medication. Metabolites were analyzed in plasma and cerebrospinal fluid of controls (n = 14), Parkinson patients receiving no L-DOPA
(n = 8), patients treated with L-DOPA without dyskinesia (n = 8), and patients with L-DOPA-induced dyskinesia (n = 10) using liquid chromatography-mass spectrometry.
We observed approximately fourfold increase in the 3-hydroxykynurenine/kynurenic acid ratio in plasma of Parkinson's patients with L-DOPA-induced dyskinesia. Anthranilic acid levels were decreased in plasma and cerebrospinal fluid of this patient group. 5-Hydroxytryptophan levels were twofold increased in all L-DOPA-treated Parkinson's patients. We conclude that a higher 3-hydroxykynurenine/kynurenic acid ratio in plasma may serve as a biomarker for L-DOPA-induced dyskinesia. Longitudinal studies including larger patients cohorts are needed to verify whether the changes observed here may serve as a prognostic marker for L-DOPA-induced dyskinesia. Keywords: 3-hydroxykynurenine, biomarkers, kynurenic acid, levodopa, metabolomics, tryptophan. J. Neurochem. (2017) 142, 756-766.
The most effective drug in the symptomatic treatment of Parkinson's disease (PD) is L-DOPA (L-3,4-dihydroxyphenylalanine), but chronic use is associated with serious motor complications, L-DOPA-induced dyskinesia (LID). LID is observed in more than half the patients after 10 years of treatment (Schapira et al. 2009 ). Risk factors for early onset LID include younger age, more severe disease at baseline, and higher daily dose of L-DOPA (Rascol et al. 2006; Cheshire et al. 2014) , but biomarkers to predict the risk of motor complications are not yet available.
Only a few studies have used metabolomic approaches to find biomarkers for PD in plasma (Bogdanov et al. 2008; Johansen et al. 2009; Roede et al. 2013; Trupp et al. 2014; Hatano et al. 2016; Wuolikainen et al. 2016) or cerebrospinal fluid (CSF) (Lewitt et al. 2013; Trupp et al. 2014; Wuolikainen et al. 2016) , but these studies have not addressed the metabolic effects of L-DOPA treatment and its long-term consequences for the development of LID. The above-mentioned metabolomic studies of blood and CSF suggested alterations in purine, tyrosine and tryptophan (TRP) metabolism in PD (Ascherio et al. 2009; Johansen et al. 2009; Lewitt et al. 2013; Trupp et al. 2014; Hatano et al. 2016) , including increased 3-hydroxykynurenine/ kynurenic acid (3-HK/KYNA) ratios in CSF from demised patients (Lewitt et al. 2013) . Most recently, a comprehensive urinary metabolic profile was reported that identified unique metabolic markers for idiopathic PD associated with the progression of disease (Luan et al. 2015a,b) , including TRP metabolites.
L-DOPA treatment has a major impact on tyrosine metabolism (De Deurwaerdere et al. 2017) , but the effect of L-DOPA on TRP metabolism and its possible role in the development of L-DOPA-induced dyskinesia has not been clarified. TRP is not only a precursor of serotonin (5-HT), but also for kynurenine (KYN), which can be degraded to several other neuroactive compounds, including KYNA (neuroprotective, antagonist of the glycine site of the N-methyl-Daspartate (NMDA) receptor), 3-HK (neurotoxic, generates free radicals), and quinolinic acid (neurotoxic, NMDA receptor agonist) (Schwarcz et al. 2012) . The KYN pathway (see Fig. 1 ) is the most important route of TRP degradation in humans.
Both pre-synaptic and post-synaptic maladaptive changes contribute to the pathophysiology of LID (Bastide et al. 2015; De Deurwaerdere et al. 2017) . Recently, we reported elevated dopamine (DA)/L-DOPA and reduced dihydroxyphenyl acetic acid/DA ratios in CSF of LID patients as compared to nondyskinetic PD patients receiving L-DOPA, suggesting increased DA release from non-DA cells and deficient DA re-uptake in PD-LID patients (Andersen et al. 2017) . In addition to uncontrolled dopamine release acting on supersensitive D1 receptors, enhanced glutamatergic signaling may contribute to LID. Experimental studies have shown that a change in the ratio of kynurenine metabolites can alter glutamatergic signaling and may protect against excitotoxicity mediated via NMDA receptors. KYN metabolism can be manipulated in vivo using tryptophan-2,3-dioxygenase or kynurenine 3-monooxygenase (KMO) inhibitors (Campesan et al. 2011; Breda et al. 2016) . Interestingly, prolonged systemic administration of the KMO inhibitor Ro 61-8048, which blocks 3-HK synthesis and increases KYNA levels in the brain, reduces LID in Parkinsonian, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys (Gregoire et al. 2008) .
Here, we investigated whether KYN metabolites in plasma or CSF are altered in PD patients as compared to controls and whether altered ratios of KYN metabolites are associated with L-DOPA use or LID.
Methods
PD patients and controls were recruited from different neurological clinics in the Region of Southern Denmark (Hospitals in Sønderborg and Odense), a private neurological practice (Esbjerg) and a neurological clinic in Region Zealand (Roskilde). Twenty-five PD patients and one Lewy body dementia (DLB) patient (details described under 'subgroups of PD patients') were included, all diagnosed by movement disorder specialists using the UK Brain Bank Criteria for idiopathic PD (20) . Control patients were referred by their physician or practicing neurologist for further neurological examination including lumbar puncture. Neither controls nor PD patients were receiving special diets, which may affect kynurenine pathway metabolism. In Table 1 , demographic and clinical data are summarized for controls and PD patients providing plasma samples. In Table S1 , patient data are summarized for CSF samples. Further clinical details of patients and controls can be found in Andersen et al. (2017) . All PD patients and controls were informed in writing and orally about the project, and gave written consent prior to participation. The project was approved by the local ethics committee of the Region of Southern Denmark (S-20130098 Five out of 14 control patients had the procedure done in a sitting position without measurement of the CSF pressure, whereas nine had the procedure done lying on the side with CSF pressure measurement before withdrawing CSF as part of their investigation. Aside from this the same steps for sampling CSF were followed as described above. CSF samples were obtained from 14 controls and 22 PD patients.
Blood sampling
Blood was drawn from the cubital fossa immediately after the lumbar puncture in both patients and controls. Four BD Vacutainer TM citrate tubes (Becton Dickinson A/S, Kgs.Lyngby, Denmark) were filled and gently turned four times to prevent coagulation. Within 30 min the four tubes were centrifuged at room temperature for 10 min at 1800 g. The plasma supernatant was evenly distributed into two 15 mL tubes and centrifuged at room temperature for 10 min at 3000 g. The supernatant was then aliquoted into Saarstedt â tubes and put on dry ice until storage at À80°C. Plasma samples were obtained from 14 controls and 26 PD patients.
Clinical rating
Clinical rating was performed on the same day as the LP procedure. PD motor symptom severity was rated in the ON-stage using the MDS-UPDRS part III (Goetz et al. 2007) . For patients using L-DOPA, this score and the unified dyskinesia rating scale (UDysRS) objective score procedure (Goetz et al. 2008) was performed approximately 50 min after drug intake. The procedures were recorded on video for later assessment. Cognitive rating was done using the mini-mental state examination (MMSE) and Montreal cognitive assessment (MOCA) scales.
Subgroups of PD patients
PD patients were divided into three groups: patients not receiving L-DOPA (PD-N, n = 8), patients receiving L-DOPA but without dyskinesia (PD-L, n = 8), and patients receiving L-DOPA and having dyskinesia (PD-LID, n = 10). A DLB patient with bradykinesia and a dopamine transporter-scan with marked bilateral decreased FP-CIT-uptake in the basal ganglia was included in the PD-L group, since this patient was treated with L-DOPA and was not dyskinetic. See Table 1 (plasma samples) and Table S1 (CSF samples) for demographic and clinical details. Patients assigned to PD-LID either had a positive UDysRS objective score (n = 8), or -these patients were recruited before the use of the UDysRS -clearly dyskinetic presentation (n = 1), or amnestic description of LID symptoms (n = 1). One patient in PD-L and one patient in PD-LID received anti-depressant medication.
Blinding of samples During LC-MS processing (see below) of plasma and CSF samples, samples were labeled with C for controls or P for patients, but it was not known whether patients were assigned to the PD-N, PD-L, or PD-LID subgroups.
Sample preparation
One hundred microliters of plasma and CSF, respectively, were thawed on ice for 1 h before addition of 350 lL 85% methanol including heavy labeled internal standards (0.05 lM C 6 -kynurenic acid (PerkinElmer, CUSN83060000EA), 2 lM D 6 -kynurenine (Cambridge isotope Laboratories, DLM-7842), and 2 lM mixture of 17 heavy isotope-labeled amino acids (Cambridge isotope Laboratories, MSK-A2-1.2). The samples were vortexed for 30 s and left at À20°C for 30 min before centrifugation at 16 000 g for 20 min. A quantity of 110 and 120 lL of supernatants from plasma and CSF, respectively, were transferred to new tubes prior to lyophilization. The lyophilized samples were resuspended in 20 lL 1% formic acid (FA).
LC-MS and data analysis
Ten microliters of sample was injected using a 1290 Infinity HPLC system (Agilent Technologies, Santa Clara, CA, USA) equipped with a Zorbax Eclipse Plus C18 guard column (2.1 9 50 mm and 1.8 lm particle size) and an analytical column (2.1 9 150 mm and 1.8 lm particle size) kept at 40°C. The compounds were eluted using a flow rate of 300 lL/min and the following composition of A (0.1% FA) and B (0.1% FA, acetonitrile) solvents: 97% A from 0 to 5 min, 97-85% A from 5 to 8 min, and 85-60% from 8 to 18 min before equilibration for 3 min with the initial conditions. Eluting metabolites were detected by a 6530 quadrupole time of flight mass spectrometer (Agilent Technologies) operated in positive ion mode scanning from 100 to 1000 m/z with the following settings: Gas temp at 300°C, drying gas at 8 L/min, nebulizer at 35 psig, sheath gas temp at 350°C, sheath gas flow at 11 min/l, VCap at 3500 V, fragmentor at 125 V, and skimmer at 65 V. Each spectrum was internally calibrated during analysis using the signals of purine (121.0509) and Hexakis 1H,1H,3H-tetrafluoropropoxy phosphazine (922.0098), which was delivered to a second needle in the ion source by an isocratic pump running with a flow of 20 lL/min.
A library with retention times obtained from synthetic standards (not available for N-formyl kynurenine), and exact mass of the metabolites of interest was constructed using MassHunter PCDL Manager v. B.07.00 (Agilent Technologies). Chromatograms for all compounds were extracted and quantified using Profinder v. B.08.00 (Agilent Technologies) with a mass tolerance of 20 ppm and retention time tolerance of 0.1 min. Chromatograms were subsequently manually validated. In-source-induced diagnostic fragments were used for validation of the identification (Table S2) . A chromatogram of a plasma sample is shown in Figure S1 . Quantitative linearity for all compounds (except N-formyl kynurenine) was tested using synthetic standards in different amounts covering the signal range of the measured endogenous metabolites ( Figure S4 ).
Statistics
Statistical differences in metabolites or ratios among controls and PD subgroups were analyzed by non-parametric ANOVA (KruskallWallis test) and shown by one or more asterisks following the compound name in the bar charts. Subsequently, PD-LID values were compared to controls and the other PD groups using Dunn's multiple comparison test. Statistical differences were calculated with and without inclusion of the DLB patient in the PD-L group. Significant differences are indicated in the bar charts, where * denotes significance levels of p < 0.05, **p < 0.005, ***p < 0.0005, and ****p < 0.00005.
Results
LC-MS was used to quantify TRP metabolites along the KYN and serotonin pathways. The levels of KYN and three of its major metabolites 3-HK, KYNA, and anthranilic acid (AA) in plasma and CSF of controls and the three PD groups are shown in Fig. 2 . Absolute quantification was done for KYN, 3-HK, and KYNA as heavy isotope-labeled versions of these were added during the extraction. AA and other metabolite levels ( Figure S2 ) were expressed as relative abundances.
Plasma KYN levels (low lM range) are about a factor 50 higher than CSF levels, whereas 3-HK and KYNA levels (nM range) are 15-20-fold higher in plasma as compared to CSF. AA levels in plasma and CSF could not directly be compared because no internal, heavy isotope-labeled standard was used. The results for these metabolites showed significant decreases for KYNA and AA in plasma of PD-LID patients. A similar trend was observed for these metabolites in CSF of PD-LID, but only the decrease in AA reached significance as compared to PD-L (with and without inclusion of the DLB patient).
Among controls, only two out of eight males and three out of six females had been fasting overnight before withdrawal of plasma or CSF. In plasma of the small non-fasting group, mean values for most metabolites were generally somewhat higher, but these differences did not reach statistical significance. Ratios of KYN metabolites were not affected by fasting status. Therefore, fasting and non-fasting controls were pooled for comparison with PD subgroups. Figure 3 shows the ratios for these and other KYN metabolites in plasma and CSF. The data indicate alterations between the different branches of KYN pathway metabolism in PD and PD-LID. In plasma, we observed significant, highly elevated 3-HK/KYNA and 3-HK/KYN ratios and significantly decreased 3-hydroxyanthranilic acid/3-HK and xanthurenic acid/3-HK ratios in PD-LID patients as compared to controls or PD-N. Excluding the two PD patients receiving anti-depressants (one in PD-L and one in PD-LID) did not alter the significant findings in plasma.
In plasma of controls, we observed significantly higher levels (t-test, p < 0.05) of some metabolites in males as compared to females: tryptophan, kynurenine, anthranilic acid, 3-hydroxyanthranilic acid, and xanthurenic acid. However, the observed male-female differences in plasma of controls cannot account for the observed differences in 3-HK/KYNA ratio between PD-LID (3 females, 7 males) and controls (6 females, 8 males) or for the observed difference in anthranilic acid between PD-L (0 females, 8 males) and PD-LID (3 females, 7 males).
Other metabolite ratios in plasma are shown in Figure S2 , with a significantly reduced KYN/TRP ratio in PD-LID as compared to PD-L and no significant differences in KYNA/ KYN and AA/KYN ratios.
In CSF, we observed a similar trend with a highly elevated mean of 3HK/KYNA in PD-LID, but because of large variation and lower n (Table S1), these changes did not reach significance. In CSF of controls, no effect of fasting status or gender was observed for any of the metabolites.
In PD patients (all groups), plasma and CSF levels of KYN (r 2 = 0.21, p = 0.03) and 3-HK (r 2 = 0.26, p = 0.02) were significantly correlated, but plasma and CSF levels of KYNA were not correlated.
We assessed also L-DOPA, 3-O-methyldopa (3-OMD), and TRP metabolites along the serotonin pathway ( Figure S2 and S3). As expected, the L-DOPA-treated PD patients (PD-L and PD-LID) showed highly elevated L-DOPA and 3-OMD levels in plasma and CSF. TRP levels in plasma and CSF were not different between controls and the three PD groups, but 5-hydroxytryptophan (5-HTP) was about twofold increased in PD-L and PD-LID.
In conclusion, we observed significant changes in KYN metabolism in PD-LID, differentiating this group not only from controls, but also from non-dyskinetic PD, that is, PD-N and PD-L.
Discussion
Here, we present evidence of an altered KYN pathway metabolism in plasma and CSF of PD patients with L-DOPA-induced dyskinesia. The overall change of KYN metabolism in PD-LID is a shift toward the production of 3-HK (Fig. 4) . The major findings are the significant decreases of AA and KYNA in plasma of dyskinetic (PD-LID) versus non-dyskinetic L-DOPA-treated PD patients (PD-L) and a significant increase of the 3-HK/KYNA ratio in plasma of PD-LID versus controls and PD-N. The presented quantitative LC-MS analysis of tryptophan and kynurenine metabolites in human plasma and CSF showed absolute levels of the measured analytes in agreement with those reported previously for plasma (Widner et al. 2002; Forrest et al. 2010; Savitz et al. 2015) and CSF (Olsson et al. 2012; Kegel et al. 2014; de Bie et al. 2016; Sellgren et al. 2016) .
The 3-HK/KYNA ratio reflects the balance between the neurotoxic and neuroprotective metabolites. An increase of this ratio may indicate increased activity of KMO in relation to kynurenine aminotransferases and kynureninase activities (see Fig. 1 ). An increased 3-HK/KYN and decreased 3HAA/ 3-HK and XA/3-HK ratios in PD-LID plasma (Fig. 3) are also in line with increased KMO activity. We did not observe significant changes in tryptophan or KYN levels in plasma or CSF, indicating that kynurenine metabolism in PD-LID is shifted toward 3-HK production -catalyzed by KMO -and a down-regulation of KYNA (via kynurenine aminotransferases) and AA (via kynureninase) synthesis. These changes were not observed in the two subgroups of non-dyskinetic PD patients, indicating that the three-to fourfold increase of 3HK/KYNA ratio in plasma or CSF may be considered a specific biomarker of LID.
The enhanced 3HK/KYNA ratio in plasma and a similar tendency in CSF suggest that a similar change in KYN metabolites occurs in the basal ganglia at the synaptic level, where it may give rise to increased glutamatergic transmission, which may facilitate LID. The rationale for this is that lower KYNA levels allow endogenous glycine to potentiate NMDA receptor function and pre-synaptic nicotinic acetylcholine receptors on glutamatergic terminals are more easily activated (Schwarcz et al. 2012) . In PD spine loss occurs on the dendrites of medium spiny striatal neurons containing dopamine D2 receptors (Neely et al. 2007) . This selective spine loss may contribute to the development of LID (Schuster et al. 2009 ). Increased levels of 3-HK, which increase oxidative stress (Okuda et al.1998) , and decreased levels of KYNA, which Abbreviations of patient groups: see legend to Table 1 . Abbreviations used for metabolites and enzymes: 3-HK: 3-hydroxykynurenine; 3-HAA: 3-hydroxyanthranilic acid; KATs: kynurenine aminotransferases; KMO: kynurenine 3-monooxygenase; KYN: kynurenine ;KYNA: kynurenic acid; KYNU: kynureninase; XA: xanthurenic acid.
increase and vulnerability for excitoxicity (Amori et al. 2009 ), may contribute to striatal spine loss and the development of LID.
In the MPTP monkey model of PD, LID symptoms can be reduced by enhancing brain KYNA production using systemic treatment with an inhibitor of kynurenine 3-monooxygenase (KMO) (Gregoire et al. 2008) . In addition, systemic inhibition of KMO shows marked neuroprotective effects in a Drosophila model of Huntington's disease (Campesan et al. 2011) . Provided that future studies confirm the present results of increased 3HK/KYNA ratios in dyskinetic PD patients, clinical intervention studies using KMO inhibitors should be considered to alleviate LID symptoms and to confirm the pathophysiological role of kynurenine metabolites in LID.
Other PD biomarker studies targeting TRP and KYN metabolites have shown increases in KYN/TRP ratio in plasma (Widner et al. 2002) and increases in 3HK/KYNA ratio in postmortem obtained CSF (Lewitt et al. 2013) . Increases of 3-HK and decreases of KYNA have been reported previously in brain tissue samples (frontal cortex, putamen, substantia nigra) of PD patients with the largest changes observed in PD patients treated with L-DOPA (Ogawa et al. 1992) . These previous studies did not address eventual differences between L-DOPA-treated PD patients with or without LID. Despite the small sample sizes of our PD subgroups, our study clearly shows that KYN pathway metabolism is changed in PD-LID with a decreased KYN/ TRP ratio and an increased 3HK/KYNA ratio, which was not present in PD-L or PD-N.
The PD-LID group is not only characterized by the presence of LID, but also by a younger age of onset and a longer duration of disease (see Table 1 ). Some of these factors, for example, more advanced PD, increased oxidative stress, increased inflammation, may contribute to the observed changes in KYN metabolism (Lim et al. 2017) .
TRP is not only degraded via the kynurenine pathway, it is also the precursor of 5-HTP and 5-HT, reactions catalyzed by TRP hydroxylase and amino acid decarboxylase. In plasma we observed about twofold increases of 5-HTP in PD-L and PD-LID as compared to controls and PD-N. This effect can be explained by the co-treatment with peripheral decarboxylase inhibitors and also competition between L-DOPA and 5-HTP, which are both substrates for aromatic amino acid decarboxylase.
In agreement with a higher daily L-DOPA intake in PD-LID patients (Table 1) , we observed slightly higher L-DOPA and 3-OMD levels in PD-LID, although not significantly different from PD-L. 3-OMD levels are much higher than L-DOPA, because it has a much longer half-life than L-DOPA (Tohgi et al. 1995) . L-DOPA and 3-OMD are, like KYN, transported into the brain via the large neutral amino acid transporter and may inhibit the transport of KYN over the blood-brain barrier and into astrocytes (Asanuma and Miyazaki 2016; Sekine et al. 2016) . A lower availability of KYN in astrocytes in PD-LID, may reduce central KYNA production. In contrast to cerebral 3-HK, which can be derived from the circulation or from production in brain microglia or macrophages, cerebral KYNA levels are almost entirely dependent on synthesis in brain astrocytes (Fukui et al. 1991; Pardridge 1998) .
Changes in KYN metabolites have been observed in other neurological and psychiatric disorders, including, Huntington's disease (Forrest et al. 2010; Byrne and Wild 2016) , schizophrenia (Forrest et al. 2010; Chiappelli et al. 2014; Kegel et al. 2014; Fazio et al. 2015; Oxenkrug et al. 2016 ) bipolar disorder, (Olsson et al. 2012; Lavebratt et al. 2014; Savitz et al. 2015; Sellgren et al. 2016 ) and other brain disorders (Vecsei et al. 2013; Lovelace et al. 2016; Watzlawik et al. 2016) . In schizophrenia and bipolar disorder increased levels of KYNA have been observed in saliva, CSF and postmortem brain tissue, whereas in Huntington's disease decreased KYNA and increased 3-HK and quinolinic acid has been observed in CSF and postmortem brain tissue. TRP metabolism is also influenced by gut microbiota with significant consequences for CNS function and dysfunction (Kennedy et al. 2017) . Thus it can be speculated that differences in gut microbiota among PD patients play a role in the response to L-DOPA therapy and the risk of developing LID.
We conclude that our present LC-MS methodology to detect KYN metabolites in body fluids provides a unique tool to monitor L-DOPA-treated PD patients for increasing risk of LID. Further validation of the 3HK/KYNA ratio as a biomarker of LID in plasma is needed in larger patient cohorts and longitudinal studies, including multiple samples from the same patients obtained before and after development of LID.
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